PAPILLOMAVIRAL CARCINOGENESIS. SIGNIFICANT ACHIEVEMENTS AND SPECIFIC CHALLENGES. PART 3. THREE LEVELS OF CERVICAL CANCER PREVENTION AND TREATMENT
https://doi.org/10.17650/1726-9784-2020-19-3-6-11
Abstract
Efficient prophylactic vaccines have been developed to prevent cervical cancer, a frequent female oncological disease caused by carcinogenic human papillomaviruses. World Health Organization worked out the program for prophylaxis of cervical cancer and control of the disease. It includes preventive adolescent vaccinations, screening of precancerous cervical lesions in women as well as cervical cancer treatment if originated. Cervical cancer diagnostics is being improved, development of therapeutic human papillomaviruses vaccines is in progress. The review deals with major achievements and certain challenges in the field of cervical cancer prevention.
Part I see: Volgareva G.M. Papillomaviral carcinogenesis. Major achievements and certain challenges. Part I. General notions of papillomaviruses. Human papillomavirusesassociated cancers. Russian Journal of Biotherapy 2020;19(1):6–12.
Part 2 see: Volgareva G.M. Papillomaviral carcinogenesis. Major achievements and certain challenges. Part 2. HPV-associated cancers in Russia. Preventive HPV vaccines. Russian Journal of Biotherapy 2020;19(2):31–8.
About the Author
G. M. Volgareva
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. World Health Organization. IARC. Monographs on the evaluation of carcinogenic risks to humans. Human Papillomaviruses. V. 90. Lyon, 2007.
2. WHO. Comprehensive cervical cancer control. A guide to essential practice. 2nd edn; Geneva, 2014. 394 p. Available by: https://apps.who.int/iris/bitstream/handle/10665/144785/9789241548953_eng.pdf;jsessionid=8FBB1D11A1D2A2B688F33202B9EEBC48?sequence=1.
3. Adamyan L.V., Artymuk N.V., Ashrafyan L.A. et al. Letter of the Ministry of Health of the Russian Federation of November 2, 2017, No 15-4/10/2-7676 оn prescription of clinical recommendations (treatment protocol) “Benign and precancerous cervical diseases with the attitude to cancer prevention”. 2017. (In Russ.). Available by: https://www.garant.ru/products/ipo/prime/doc/71716538/.
4. Papanicolaou G.N. A new procedure for staining vaginal smears. Science 1942;95(2469):438–9. DOI: 10.1126/science.95.2469.438.
5. El-Zein M., Richardson L., Franco E.L. Cervical cancer screening of HPV vaccinated populations: cytology, molecular testing, both or none. J Clin Virol 2016;76(Suppl. 1):62–8. DOI: 10.1016/j.jcv.2015.11.020.
6. Canfell K., Caruana M., Gebski V. et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. PloS Med 2017;14(9):1002388. DOI: 10.1371/journal.pmed.1002388.
7. Klaes R., Benner A., Friedrich T. et al. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2002;26(11):1389–99. DOI: 10.1097/00000478-200211000-00001.
8. Sano T., Oyama T., Kashiwabara K. et al. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998;153(6):1741–8. DOI: 10.1016/S0002-9440(10)65689-1.
9. Klaes R., Friedrich T., Spitkovsky D. et al. Overexpression of p16(INK4 A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92(2):276–84. DOI: 10.1002/ijc.1174.
10. Volgareva G., Zavalishina L., Andreeva Yu. et al. Protein p16 as a marker of dysplastic and neoplastic alterations in cervical epitelial cells. BMC Cancer 2004;4:58. DOI: 10.1186/1471-2407-4-58.
11. Serrano M., Hannon G., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 . Nature 1993;366(6456):704–7. DOI: 10.1038/366704a0.
12. Ruas M., Peters G. The p16INK4 a/ CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998;1378(2):115–77. DOI: 10.1016/s0304-419x(98)00017-1.
13. Dyson N., Howley P.M., Münger K., Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243(4893):934–7. DOI: 10.1126/science.2537532.
14. Lowe S.W., Sherr C.J. Tumor suppression by Ink4 a-Arf: progress and puzzles. Curr Opin Genet Dev 2003;13(1):77–83. DOI: 10.1016/s0959-437x(02)00013-8.
15. Kishore V., Patil A.G. Expression of p16INK4A protein in cervical intraepithelial neoplasia and invasive carcinoma of uterine cervix. J Clin Diagn Res 2017;11(9):17–20. DOI: 10.7860/JCDR/2017/29394.10644.
16. Yu L.L., Guo H.Q., Lei X.Q. et al. p16/Ki-67 co-expression associates high risk human papillomavirus persistence and cervical histopathology: a 3-year cohort study in China. Oncotarget 2016;7(40):64810–9. DOI: 10.18632/oncotarget.11705.
17. Sun H., Shen K., Cao D. Progress in immunocytochemical staining for cervical cancer screening. Cancer Manag Res 2019;11:1817–27. DOI: 10.2147/CMAR.S195349.
18. Volgareva G.M. Papillomaviral carcinogenesis. Major achievements and certain challenges. Part 2. HPV-associated cancers in Russia. Preventive HPV vaccines. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2020;19(2):31–8. (In Russ.).
19. Thomas K.J., Smith K.L., Youde S.J. et al. HPV16 E6 29-38-specific T cells kill cervical carcinoma cells despite partial evasion of T-cell effector function. Int J Cancer 2008; 122(12): 2791–9. DOI: 10.1002/ijc.23475.
20. Van der Burg S.H., Melief C.J. Therapeutic vaccination against human papilloma virus induced malignancies. Curr Opin Immunol 2011;23(2):252–7. DOI: 10.1016/j.coi.2010.12.010.
21. Santin A.D., Bellone S., Roman J.J. et al. Therapeutic vaccines for cervical cancer: dendric cell-based immunotherapy. Curr Pharm Des 2005;11(27):3485–500. DOI: 10.2174/138161205774414565.
22. Palucka K., Banchereau J. Dendriticcell-based therapeutic cancer vaccines. Immunity 2013;39(1):38–48. DOI: 10.1016/j.immuni.2013.07.004.
23. Chabeda A., Yanez R.J.R., Lamprecht R. et al. Therapeutic vaccines for high-risk HPV-associated diseases. Papillomavirus Res 2018;5:46–58. DOI: 10.1016/j.pvr.2017.12.006.
Review
For citations:
Volgareva G.M. PAPILLOMAVIRAL CARCINOGENESIS. SIGNIFICANT ACHIEVEMENTS AND SPECIFIC CHALLENGES. PART 3. THREE LEVELS OF CERVICAL CANCER PREVENTION AND TREATMENT. Russian Journal of Biotherapy. 2020;19(3):6-11. (In Russ.) https://doi.org/10.17650/1726-9784-2020-19-3-6-11
Views:
326
Email this article 
